Boston extends M&A activity with $375m deal for Atritech
This article was originally published in Clinica
Executive Summary
Boston Scientific today agreed to acquire Atritech, a specialist in left atrial appendage closure technology. The deal, its fourth M&A agreement in as many months, marks Boston's strategy to bulk up its portfolio of minimally-invasive cardiovascular devices.